

# Special Issue

## Proteomics and Personalized Medicine

### Message from the Guest Editor

The first successful applications in personalized medicine were made possible largely in part by the advent of next-generation sequencing techniques. The use of proteomics for personalized medicine was hampered by technical limitations, such as high-throughput measurements. However, the field of proteomics is evolving at a fast pace now, and recent breakthroughs will make proteomics a valuable asset in the arsenal of techniques used in personalized medicine. In this Special Issue, we want to present some of the latest technical developments in proteomics that will enable its use in personalized medicine and also pioneering applications. Therefore, we are looking for interesting cutting-edge contributions to our journal that use proteomics, from hardware to data analysis, for personalized medicine or that facilitate the implantation therein.

---

### Guest Editor

Prof. Dr. Kurt Boonen

Centre for Proteomics, UAntwerp, Antwerp, Belgium. Unit Environmental Risk & Health, VITO, Mol, Belgium

---

### Deadline for manuscript submissions

closed (5 November 2020)



# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/39581](http://mdpi.com/si/39581)

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
jpm@mdpi.com

[mdpi.com/journal/  
jpm](http://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](http://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).